GS-4104 (Gilead Sciences Inc).

GS-4104 (Gilead Sciences Inc). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

GS-4104 (Gilead Sciences Inc). Abstract Text:

Gilead and Roche are codeveloping GS-4104, a neuraminidase inhibitor, for the potential treatment and prevention of influenza virus infections, type A and type B. The companies began international phase II/III trials in December 1997 [272638]. The phase II/III double-blind, placebo-controlled study involves centers in the US, Canada, Europe and Hong Kong [272638]. The program will consist of two treatment studies and two prophylaxis studies, each of which will recruit 750 patients [273331]. The trials involve over 1500 patients, who will receive either GS-4104 or placebo for 6 weeks, as a once- or twice-daily dosing schedule [276650], [276895]. The company has also registered 73 centers for the two treatment studies, and 55 of these had been activated by the end of January 1998. Patients in the treatment arm will receive either GS-4104 or placebo for 5 days. Roche is conducting similar trials in Europe, Canada and Hong Kong [276895]. In September 1997, results were announced from two phase II studies, initiated in May 1997, in which volunteers were exposed intranasally to influenza A. The patients received oral capsules of GS-4104, or placebo, once-daily or twice-daily. In the first study, GS-4104 decreased the duration of symptoms by nearly 50%. In the second study, all patients who were given GS-4104 prophylactically did not have detectable levels of virus, as compared to 50% in the placebo group [264362]. In phase I trials, GS-4104 was well-tolerated with good oral absorption and distribution in blood and tissue [248180].

GS-4104 (Gilead Sciences Inc). Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

GS-4104 (Gilead Sciences Inc). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: IDrugs : the investigational drugs journal

VOLUME: 1

Page Numbers: 122-8

Journal Abbreviation:

ISSN: 1369-7056

DAY: 9

MONTH: May

YEAR: 1998

GS-4104 (Gilead Sciences Inc). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100883655

GS-4104 (Gilead Sciences Inc). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: GS-4104 (Gilead Sciences Inc). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for GS-4104 (Gilead Sciences Inc).

AFFILIATION: Novartis Research Institute, General Dermatology, PO Box 80, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: IDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

GS-4104 Gilead Sciences Inc Related Publications

• Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
• Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
• GS-4104 (Gilead Sciences Inc).
• NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
• Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
• [Analytic developmental blood serum examinations in female genital carcinoma (paper electrophoresis).]
• [Contribution to the treatment of the pelvic presentation delivery. (Clinical experience report)]
• [Differential diagnosis of genital tumors & floating spleens.]
• [HABITUAL STILLBIRTHS IN ADVANCED DIFFUSE SCLERODERMIA.]
• [On a congenital skull impression not explainable by labor mechanics in a newborn infant.]
• [Unusual angioma-like vascular hyperplasia in vagina and uterus.]